Western pharma firms strategically license assets from Chinese biotechs while leaving China rights with the local partner. This leverages China's faster, cheaper clinical development, as the partner tests the molecule in new indications, generating valuable data that de-risks the asset for the global firm at no extra cost.

The "NewCo" model, where a new company is formed around assets licensed from an existing firm, is a key strategy for Western investors to access a deep well of innovation from Chinese companies like Heisco, which are largely unknown in the West but possess broad, innovative pipelines.

While pharma companies are increasingly licensing assets from Chinese biotechs, they are not acquiring them. This dichotomy highlights how geopolitical tensions and logistical complexities are creating a ceiling on US-China biotech integration, limiting partnerships to licensing-in rather than full M&A.

China has developed a first-rate biotech effort, enabling U.S. firms to buy or license preclinical assets more efficiently than building them domestically. This creates an arbitrage opportunity, leveraging China's R&D capabilities while relying on U.S. expertise and capital for global commercialization.

While innovation from China is increasingly integrated into Western pharma pipelines, there's little expectation of outright acquisitions of Chinese companies. The consensus is that licensing a specific asset is far simpler and avoids the significant political and regulatory complexities of a full M&A transaction.

Big Pharma's strategy differs by region: they are willing to acquire innovative US biotechs outright but prefer to only license assets from Chinese companies. This is because Chinese assets can be secured at significantly lower valuations without the complexities of a full M&A transaction, creating an exit dilemma for VCs in China.

To capitalize on promising Chinese biotech assets while mitigating risks in IP and manufacturing (CMC), investors are creating new US-based companies ("NewCos"). This structure allows an experienced US leadership team and board to guide the asset's development to meet global regulatory standards.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

Big Pharma is increasingly licensing assets from Chinese biotechs, putting the region on par with Europe as a source of innovation. However, outright M&A of Chinese firms is a complete non-starter. This reflects a bifurcated strategy: pharma will partner for assets but avoids the geopolitical and logistical headaches of acquisitions, creating a 'license-only' pipeline from China.